Kimyrsa and Orbactiv – A Tale of Two Formulations
Brittany T Jackson,1 David B Cluck,2 Andrés F Henao-Martínez,3 Daniel B Chastain4 1Department of Pharmacy, Mount Sinai Morningside, New York, NY, 10025, USA; 2Department of Pharmacy Practice, Bill Gatton College of Pharmacy East Tennessee State University, Johnson City, TN, 37614, USA; 3Division of...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-03-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/kimyrsa-and-orbactiv--a-tale-of-two-formulations-peer-reviewed-fulltext-article-DDDT |
| _version_ | 1811155650660532224 |
|---|---|
| author | Jackson BT Cluck DB Henao-Martínez AF Chastain DB |
| author_facet | Jackson BT Cluck DB Henao-Martínez AF Chastain DB |
| author_sort | Jackson BT |
| collection | DOAJ |
| description | Brittany T Jackson,1 David B Cluck,2 Andrés F Henao-Martínez,3 Daniel B Chastain4 1Department of Pharmacy, Mount Sinai Morningside, New York, NY, 10025, USA; 2Department of Pharmacy Practice, Bill Gatton College of Pharmacy East Tennessee State University, Johnson City, TN, 37614, USA; 3Division of Infectious Diseases, University of Colorado, Anschutz Medical Campus, Aurora, CO, 80045, USA; 4Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Albany, GA, 31701, USACorrespondence: Brittany T Jackson, Department of Pharmacy, Mount Sinai Morningside, New York, NY, 10025, USA, Email brittany.jackson@mountsinai.orgAbstract: Kimyrsa is a new formulation (NF) of the original formulation of oritavancin ([OF] Orbactiv). Comparatively, the obvious benefit with this product is the shortened infusion time and flexibility with solution compatibility, but otherwise maintains a similar pharmacokinetic and microbiologic profile. At present, the NF lacks significant real-world experience relative to other available lipoglycopeptides and thus its place in therapy remains difficult to predict but would not be expected to be significantly different than its OF.Keywords: Kimyrsa, Orbactiv, oritavancin, glycopeptides, ABSSSI, soft tissue infections, pharmacokinetics |
| first_indexed | 2024-04-10T04:38:05Z |
| format | Article |
| id | doaj.art-f323bb65eec442a18cdb307e35566561 |
| institution | Directory Open Access Journal |
| issn | 1177-8881 |
| language | English |
| last_indexed | 2024-04-10T04:38:05Z |
| publishDate | 2023-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj.art-f323bb65eec442a18cdb307e355665612023-03-09T16:47:04ZengDove Medical PressDrug Design, Development and Therapy1177-88812023-03-01Volume 1773774282129Kimyrsa and Orbactiv – A Tale of Two FormulationsJackson BTCluck DBHenao-Martínez AFChastain DBBrittany T Jackson,1 David B Cluck,2 Andrés F Henao-Martínez,3 Daniel B Chastain4 1Department of Pharmacy, Mount Sinai Morningside, New York, NY, 10025, USA; 2Department of Pharmacy Practice, Bill Gatton College of Pharmacy East Tennessee State University, Johnson City, TN, 37614, USA; 3Division of Infectious Diseases, University of Colorado, Anschutz Medical Campus, Aurora, CO, 80045, USA; 4Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Albany, GA, 31701, USACorrespondence: Brittany T Jackson, Department of Pharmacy, Mount Sinai Morningside, New York, NY, 10025, USA, Email brittany.jackson@mountsinai.orgAbstract: Kimyrsa is a new formulation (NF) of the original formulation of oritavancin ([OF] Orbactiv). Comparatively, the obvious benefit with this product is the shortened infusion time and flexibility with solution compatibility, but otherwise maintains a similar pharmacokinetic and microbiologic profile. At present, the NF lacks significant real-world experience relative to other available lipoglycopeptides and thus its place in therapy remains difficult to predict but would not be expected to be significantly different than its OF.Keywords: Kimyrsa, Orbactiv, oritavancin, glycopeptides, ABSSSI, soft tissue infections, pharmacokineticshttps://www.dovepress.com/kimyrsa-and-orbactiv--a-tale-of-two-formulations-peer-reviewed-fulltext-article-DDDTkimyrsaorbactivoritavancinglycopeptidesabsssisoft tissue infectionspharmacokinetics |
| spellingShingle | Jackson BT Cluck DB Henao-Martínez AF Chastain DB Kimyrsa and Orbactiv – A Tale of Two Formulations Drug Design, Development and Therapy kimyrsa orbactiv oritavancin glycopeptides absssi soft tissue infections pharmacokinetics |
| title | Kimyrsa and Orbactiv – A Tale of Two Formulations |
| title_full | Kimyrsa and Orbactiv – A Tale of Two Formulations |
| title_fullStr | Kimyrsa and Orbactiv – A Tale of Two Formulations |
| title_full_unstemmed | Kimyrsa and Orbactiv – A Tale of Two Formulations |
| title_short | Kimyrsa and Orbactiv – A Tale of Two Formulations |
| title_sort | kimyrsa and orbactiv ndash a tale of two formulations |
| topic | kimyrsa orbactiv oritavancin glycopeptides absssi soft tissue infections pharmacokinetics |
| url | https://www.dovepress.com/kimyrsa-and-orbactiv--a-tale-of-two-formulations-peer-reviewed-fulltext-article-DDDT |
| work_keys_str_mv | AT jacksonbt kimyrsaandorbactivndashataleoftwoformulations AT cluckdb kimyrsaandorbactivndashataleoftwoformulations AT henaomartinezaf kimyrsaandorbactivndashataleoftwoformulations AT chastaindb kimyrsaandorbactivndashataleoftwoformulations |